Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
195.13 USD | -1.19% | +3.39% | +12.12% |
Jan. 07 | UBS Adjusts Price Target on CDW to $220 From $233, Keeps Buy Rating | MT |
Dec. 16 | Morgan Stanley Adjusts Price Target on CDW to $193 From $190, Keeps Equalweight Rating | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.34 | 8.56 | 8.17 | 8.47 | 8.32 | |||||
Return on Total Capital | 14.94 | 13.73 | 12.99 | 13.53 | 13.27 | |||||
Return On Equity % | 76.14 | 69.86 | 98.72 | 96.54 | 60.58 | |||||
Return on Common Equity | 76.14 | 69.86 | 98.72 | 96.54 | 60.58 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 16.86 | 17.38 | 17.14 | 19.73 | 21.76 | |||||
SG&A Margin | 10.57 | 10.95 | 10.06 | 12.22 | 13.54 | |||||
EBITDA Margin % | 7.77 | 8.74 | 7.99 | 8.73 | 9.49 | |||||
EBITA Margin % | 7.5 | 7.58 | 7.79 | 8.49 | 9.25 | |||||
EBIT Margin % | 6.29 | 6.43 | 7.08 | 7.51 | 8.23 | |||||
Income From Continuing Operations Margin % | 4.09 | 4.27 | 4.75 | 4.69 | 5.17 | |||||
Net Income Margin % | 4.09 | 4.27 | 4.75 | 4.69 | 5.17 | |||||
Net Avail. For Common Margin % | 4.09 | 4.27 | 4.75 | 4.69 | 5.17 | |||||
Normalized Net Income Margin | 3.29 | 3.42 | 3.97 | 4.05 | 4.47 | |||||
Levered Free Cash Flow Margin | 4.15 | 4.72 | 2.64 | 4.29 | 6.22 | |||||
Unlevered Free Cash Flow Margin | 4.7 | 5.25 | 3.09 | 4.91 | 6.89 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 2.38 | 2.13 | 1.85 | 1.8 | 1.62 | |||||
Fixed Assets Turnover | 55.4 | 46.1 | 63.31 | 68.9 | 64.55 | |||||
Receivables Turnover (Average Receivables) | 6.36 | 5.94 | 5.28 | 5.09 | 4.56 | |||||
Inventory Turnover (Average Inventory) | 28.14 | 22.25 | 20.45 | 22.07 | 22.78 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.24 | 1.53 | 1.27 | 1.33 | 1.23 | |||||
Quick Ratio | 1.02 | 1.28 | 1.05 | 1.11 | 1.05 | |||||
Operating Cash Flow to Current Liabilities | 0.29 | 0.34 | 0.15 | 0.27 | 0.29 | |||||
Days Sales Outstanding (Average Receivables) | 57.42 | 61.58 | 69.12 | 71.75 | 80.11 | |||||
Days Outstanding Inventory (Average Inventory) | 12.97 | 16.45 | 17.85 | 16.54 | 16.02 | |||||
Average Days Payable Outstanding | 41.1 | 46.6 | 54.51 | 57.21 | 62.72 | |||||
Cash Conversion Cycle (Average Days) | 29.28 | 31.43 | 32.47 | 31.09 | 33.41 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 407 | 358.21 | 1.07K | 414.69 | 307.16 | |||||
Total Debt / Total Capital | 80.28 | 78.18 | 91.42 | 80.57 | 75.44 | |||||
LT Debt/Equity | 355.55 | 310.33 | 983.42 | 376.82 | 254.38 | |||||
Long-Term Debt / Total Capital | 70.13 | 67.73 | 84.34 | 73.21 | 62.48 | |||||
Total Liabilities / Total Assets | 88 | 86.12 | 94.65 | 87.79 | 84.62 | |||||
EBIT / Interest Expense | 7.11 | 7.67 | 9.76 | 7.57 | 7.76 | |||||
EBITDA / Interest Expense | 9.37 | 10.76 | 11.36 | 9.06 | 9.23 | |||||
(EBITDA - Capex) / Interest Expense | 7.89 | 9.74 | 10.7 | 8.52 | 8.58 | |||||
Total Debt / EBITDA | 2.62 | 2.79 | 4.39 | 3.11 | 3 | |||||
Net Debt / EBITDA | 2.51 | 1.94 | 4.24 | 2.97 | 2.72 | |||||
Total Debt / (EBITDA - Capex) | 3.11 | 3.08 | 4.66 | 3.31 | 3.23 | |||||
Net Debt / (EBITDA - Capex) | 2.99 | 2.15 | 4.5 | 3.15 | 2.93 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.03 | 2.41 | 12.74 | 14.06 | -9.99 | |||||
Gross Profit, 1 Yr. Growth % | 12.3 | 5.6 | 11.16 | 31.33 | -0.73 | |||||
EBITDA, 1 Yr. Growth % | 11.8 | 15.18 | 3.4 | 24.61 | -2.16 | |||||
EBITA, 1 Yr. Growth % | 11.76 | 3.48 | 16.2 | 24.3 | -1.93 | |||||
EBIT, 1 Yr. Growth % | 14.82 | 4.77 | 24.42 | 21.05 | -1.4 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 14.59 | 7.02 | 25.38 | 12.74 | -0.92 | |||||
Net Income, 1 Yr. Growth % | 14.59 | 7.02 | 25.38 | 12.74 | -0.92 | |||||
Normalized Net Income, 1 Yr. Growth % | 12.99 | 6.43 | 27.8 | 16.31 | -0.64 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 19.09 | 9.22 | 29.17 | 15.48 | -0.37 | |||||
Accounts Receivable, 1 Yr. Growth % |